Proliferation signal inhibitor toxicities after thoracic transplantation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 63-77

  Ensor, Christopher R ^a   Doligalski, Christina T ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

Heart; Lung; Mammalian target of rapamycin; Proliferation signal inhibitor; Toxicity; Transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FK 506 BINDING PROTEIN; I KAPPA B ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR REL; VASCULOTROPIN;

ACNE; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CREATININE CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FIBROBLAST; FIBROSIS; FIRST PASS EFFECT; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ABSORPTION; LIVER DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CAVITATION; LUNG DIFFUSION CAPACITY; LUNG GRAFT REJECTION; LUNG HEMORRHAGE; LUNG TOXICITY; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MEDIASTINITIS; MULTICENTER STUDY (TOPIC); MYCOSIS; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PERICARDIAL EFFUSION; PLASMA PROTEIN BINDING; PLEURA EFFUSION; PNEUMONIA; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SURGICAL APPROACH; THROMBOSIS; TREATMENT INDICATION; VIRUS REPLICATION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ANIMALS; CELL PROLIFERATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; SIROLIMUS;

CHICKEN ANEMIA VIRUS; CYTOMEGALOVIRUS; MAMMALIA;

EID: 84871249314     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.726219     Document Type: Review

References (89)

1. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40 (Pubitemid 28385231)
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S (Pubitemid 36547910)
3. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30:2192-4 (Pubitemid 28399473)
4. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42 (Pubitemid 27327197)
5. Crowe A, Bruelisauer A, Duerr L, et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27:627-32 (Pubitemid 29214476)
6. U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Rapamune prescribing information. Available from: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 12 March 2012]
7. U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Zortress prescribing information. Available from: http://www. accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed 12 March 2012]
8. U.S. Department of Health and Human Services/U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors, and inducers. Available from: http://www.fda.gov/drugs/ developmentapprovalprocess/ developmentresources/ druginteractionslabeling/ ucm093664. htm#classInhibit [Accessed 12March 2012]
9. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008;27:141-9 (Pubitemid 351221042)
10. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86 (Pubitemid 44030320)
11. Valentine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26:557-64
12. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced-incidence of de novo malignancies. Transplantation 2005;80:883-9 (Pubitemid 41552882)
13. Chen F, Omasa M, Kondo N, et al. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. Ann Thorac Surg 2009;87:e6-7
14. Morton JM, McLean C, Booth SS, et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008;27:462-5 (Pubitemid 351418242)
15. Potena L, Bianchi IG, Magnani G, et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010;89:263-5
16. Potena L, Prestinenzi P, Bianchi IG, et al. Cyclosporine lowering with everolimus or mycophenolate mofetil in heart transplant recipients: long-term follow-ip of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 2012;31:565-70
17. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010;89:864-72
18. Arora S, Gude E, Sigurdardottir V, et al. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012;31:259-65
19. Zuckermann A, Keogh A, Crespo-Leiro MG, et al. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant 2012; Epub ahead of print
20. Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006;25:518-22
21. Vigano M, Dengler T, Mattei MF, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized multicenter study. Transpl Infect Dis 2010;12:23-30
22. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 2007;21:149-58
23. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84:1436-42 (Pubitemid 350294718)
24. Ross H, Kfoury AG, Van Balek A, et al. Lower incidence of viral infections with everolimus versus MMF in de novo heart transplant recipients: 12 month analysis of a randomized multicenter study. J Heart Lung Transplant 2011;30:171s
25. Potena L, Bianchi IG, D'Agostino C, et al. Everolimus treatment reduces the need for anti-CMV prophylaxis in de novo heart transplant recipients. J Heart Lung Transplant 2011;30:172s
26. Demopoulos L, Pollinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40:1407-10 (Pubitemid 351853135)
27. Delgado JF, Manito N, Almenar L, et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011;13:136-44
28. Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012;12:1458-68
29. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011;11:654-9
30. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-13
31. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77:275-80 (Pubitemid 38155758)
32. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006;6:169-77 (Pubitemid 43382215)
33. Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011;183:379-87
34. Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006;81:355-60 (Pubitemid 43255719)
35. Kobashigawa J, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
36. Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007;21:536-43 (Pubitemid 47161833)
37. Pauly D, Starling R, Kobashigawa J, et al. Heart transplant recipients treated with everolimus have less increase in intimal thickness vs. MMF, irrespective of lipid values. J Heart Lung Transplant 2011;30:57s
38. Kobashigawa J, Pauly D, Ross H, et al. Reduction of cardiac allograft vasculopathy with everolimus over mycophenolate mofetil: intravascular ultrasound results of a randomized multicenter trial. J Heart Lung Transplant 2011;30:52S
39. Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation 2011;92:235-43
40. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58 (Pubitemid 37025404)
41. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700 (Pubitemid 39453021)
42. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53 (Pubitemid 36859019)
43. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-33 (Pubitemid 350291245)
44. Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012;125:708-20
45. Epailly E, Albanell J, Andreassen A, et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant 2011;25:E475-86
46. Ahya VN, McShane PJ, Baz MA, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011;30:175-81
47. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-20 (Pubitemid 38758188)
48. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004;78:1362-6 (Pubitemid 39507977)
49. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;6:429-33 (Pubitemid 43382183)
50. Laugharne M, Cross S, Richards S, et al. Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. Transplantation 2007;83:1635-8 (Pubitemid 46987917)
51. Rodrigo E, Santos L, Pinera C, et al. Early prediction of new-onset diabetes mellitus by fifth-day fasting plasma glucose, pulse pressure, and proteinuria. Transplant Proc 2011;43:2208-10
52. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
53. Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 2010;55:213-16
54. Bertoni E, Bruschi M, Candiano G, et al. Posttransplant proteinuria associated with everolimus. Transplant Proc 2009;41:1216-17
55. Oroszlan M, Bieri M, Ligeti N, et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010;23:125-32
56. Serkova N, Litt L, James TL, et al. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther 1999;289:800-6 (Pubitemid 29191234)
57. Aliabadi AZ, Mahr S, Dunkler D, et al. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008;86:1771-6
58. Stephany BR, Boumitri M, Budev M, et al. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009;28:564-71
59. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007;84:467-74 (Pubitemid 47312156)
60. Roman A, Ussetti P, Zurbano F, et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011;43:2693-8
61. Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int 2011;24:627-36
62. Zuckermann A, Arizon JM, Dong G, et al. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation 2011;92:594-600
63. Kondo T, Ishida Y. Molecular pathology of wound healing. Forensic Sci Int 2010;203:93-8
64. Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995;59:390-5
65. Ekici Y, Emiroglu R, Ozdemir H, et al. Effect of rapamycin on wound healing: an experimental study. Transplant Proc 2007;39:1201-3 (Pubitemid 46764935)
66. Kahn D, Spearman CW, Mall A, et al. The effect of rapamycin on the healing of the ureteric anastomosis and wound healing. Transplant Proc 2005;37:830-1 (Pubitemid 40590715)
67. van der Vliet JA, Willems MC, de Man BM, et al. Everolimus interveres with healing of experimental intestinal anastamoses. Transplantation 2006;82:1477-83 (Pubitemid 44967631)
68. Lepelletier D, Perron S, Bizouarn P, et al. Surgical-site infection after cardiac surgery: incidence, microbiology, and risk factors. Infect Control Hosp Epidemiol 2005;26:466-72 (Pubitemid 40695280)
69. Carrier M, Perrault LP, Pellerin M, et al. Sternal wound infection after heart transplantation: incidence and results with aggressive surgical treatment. Ann Thorac Surg 2001;72:719-23 (Pubitemid 32846215)
70. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006;6:986-92 (Pubitemid 44356648)
71. Kshettry VR, Kroshus TJ, Hertz MI, et al. Early and late airway complications after lung transplantation: incidence and management. Ann Thorac Surg 1997;63:1576-83 (Pubitemid 27321517)
72. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004;23:632-8 (Pubitemid 38595752)
73. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003;75:1437-43 (Pubitemid 36597273)
74. Dutly AE, Gaspert A, Inci I, et al. The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur J Cardiothorac Surg 2003;24:154-8 (Pubitemid 36802356)
75. Willems MC, van der Vliet JA, de Man BM, et al. Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010;18:98-104
76. Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005;19:698-703 (Pubitemid 41341705)
77. Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004;79:541-5 (Pubitemid 38401774)
78. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-90 (Pubitemid 32879846)
79. Banerjee SK, Santhanakrishnan K, Tsui S, et al. Cavitatory lung disease in thoracic transplant recipients receiving sirolimus. J Heart Lung Transplant 2012;31:548-51
80. Chhajed PN, Dickenmann M, Bubendorf L, et al. Pattern of pulmonary complications associated with sirolimus. Resipration 2006;73:367-74 (Pubitemid 43725797)
81. Howard L, Gopalan D, Griffiths M, Mahadexa R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 2006;129:1718-21 (Pubitemid 43895005)
82. Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006;25:241-4 (Pubitemid 43156379)
83. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003;22:210-13 (Pubitemid 36173681)
84. Garcia-Luque A, Cordero E, Torello J, et al. Sirolimus-associated pneumonitis in heart transplant recipients. Ann Pharmacother 2008;42:1143
85. Otton J, Hayward CS, Keogh AM, et al. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2009;28:104-6
86. Exposito V, Vazquez JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008;27:797-800
87. Zuckermann A, Arizon J, Eisen H, et al. Risk factors for pericardial and pleural effusions in heart transplant recipients exposed to everolimus, azathioprine, or MMF. J Heart Lung Transplant 2011;30:244s
88. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011;11:654-9
89. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007;19:162-72 (Pubitemid 46810293)